The genetic data supporting the role of p53 in ACC has improved the early diagnosis of ACC in TP53 mutation carriers through asymptomatic screening.5,21 However, targeting p53 in either the preventative or therapeutic setting remains a challenge.1 The identification of other more druggable gene targets with genetic associations with ACC could prove useful, whereby SNPs in genes that associate with differential ACC cancer risk in TP53 mutation carriers could help to identify novel druggable genes and/or pathways. The gene discussed is TP53; the disease is cancer.